Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

Related Articles

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

Cancer Treat Rev. 2012 Oct;38(6):767-75

Authors: Diaz-Padilla I, Duran I, Clarke BA, Oza AM

Abstract

Advanced recurrent gynecological malignancies have a poor prognosis despite systemic treatment, which is usually cytotoxic chemotherapy. Responses are generally short-lived and more effective treatments are needed. Rationally designed molecularly targeted therapy is an emerging and important option in this setting. The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase of the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway with a critical role in controlling cancer cellular growth, metabolism and cell cycle progression. Aberrant PI3K-dependent signaling occurs frequently in a wide range of tumor types, including ovarian, endometrial and cervical cancer. Early clinical studies of first-generation mTOR inhibitors have shown promising clinical activity in endometrial cancer. However, the molecular basis of sensitivity and resistance to these agents remains largely unknown. In this review, we will update the clinical and biological data underlying the development of first generation mTOR inhibitors in the treatment of gynecological tumors. The role of potential new combination regimens with mTOR inhibitors in gynecological cancers will also be discussed.

PMID: 22381585 [PubMed - indexed for MEDLINE]

Sent from my iPhone